https://www.pharmaceutical-technology.com/data-insights/zongertinib-boehringer-ingelheim-international-non-small-cell-lung-cancer-likelihood-of-approval/
Zongertinib is under clinical development by Boehringer Ingelheim International and currently in Phase I for Non-Small Cell Lung Cancer.
boehringer ingelheimsmall cellzongertinibinternationalnon